Answers are grounded in this paper and cite their sources.
Multicenter retrospective observational study shows tirzepatide improves metabolic outcomes in type 2 diabetes, highlighting its effectiveness.
Tirzepatide demonstrated robust clinical efficacy and a favourable safety profile in a real-world clinical setting, regardless of whether incretin-based therapy had been administered previously.
No takes yet. Share an insight, caveat, or question.
Maruyama et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: